Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant

Cancer. 2013 Dec 1;119(23):4188-95. doi: 10.1002/cncr.28323. Epub 2013 Sep 16.

Abstract

Background: Few studies have examined the acute effects of autologous hematopoietic stem cell transplantation (Au-HSCT) on the neuropsychological functioning of patients with multiple myeloma (MM). The prevalence of cognitive deficits after induction chemotherapy (pre-AuHSCT) was examined in patients with MM, clinically significant changes in cognitive function 1 and 3 months post-AuHSCT were determined, and patients who may be vulnerable to cognitive decline during this period were identified.

Methods: A total of 53 patients with MM were recruited pre-AuHSCT. Neuropsychological tests measuring multiple cognitive domains (attention, psychomotor speed, learning/memory, language, executive function, motor function) were administered pre-AuHSCT and 1 and 3 months post-AuHSCT. A pretreatment assessment was not available. An Overall Cognitive Function Index was computed to determine cognitive impairment pre-AuHSCT, and a practice-effect-adjusted Reliable Change Index was used to determine cognitive change over time.

Results: Overall, deficits were more frequent in learning/memory, executive function, motor function, and psychomotor speed. Before AuHSCT, 47% of patients (25/53) exhibited cognitive impairment as determined by the Overall Cognitive Function Index. One month post-AuHSCT, 49% of patients (20/41) demonstrated clinically significant decline on 1 or more measures; 3 months post-AuHSCT, 48% (14 of 29 patients) showed decline on 1 or more measures. Older patients, minorities, and those with advanced disease, more induction cycles, or postinduction deficits showed greater vulnerability to decline.

Conclusions: Nearly half of the patients showed vulnerability to impairment in learning/memory or executive function after receiving induction therapy, and the prevalence of impairment remained high post-AuHSCT. Awareness of cognitive impairment and associated risk factors in actively treated patients is important for considering psychosocial or other support for patients with acute cognitive symptoms.

Keywords: MDASI; autologous transplant; cognitive impairment; induction chemotherapy; multiple myeloma; neuropsychological testing; patient-reported outcomes.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Cognition Disorders / etiology*
  • Executive Function / physiology
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Learning / physiology
  • Longitudinal Studies
  • Male
  • Memory / physiology
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / therapy*
  • Transplantation, Autologous